Filing Flows › Comparisons › ALLO vs FDMT
Allogene Therapeutics vs 4D Molecular Therapeutics: ALLO and FDMT compared
Allogene Therapeutics is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $3.8M for 4D Molecular Therapeutics (Q2 2026).
Where the money goes: ALLO and FDMT
Allogene Therapeutics (ALLO) · Q2 2026
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
4D Molecular Therapeutics (FDMT) · Q2 2026
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
| Allogene Therapeutics (ALLO) | 4D Molecular Therapeutics (FDMT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $4.6M | $3.8M |
| Revenue growth, Y/Y | — | 252× |
| Operating margin | n/m | n/m |
| Net earnings | −$42.7M | −$72.9M |
| Net margin | -919.8% | — |
| Operating cash flow | −$32.0M | −$70.0M |
Questions
Which is bigger, Allogene Therapeutics or 4D Molecular Therapeutics?
Allogene Therapeutics is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $3.8M for 4D Molecular Therapeutics (Q2 2026).
More: Allogene Therapeutics earnings · how Allogene Therapeutics makes money · 4D Molecular Therapeutics earnings · how 4D Molecular Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.